A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

DECADES of virology research that yielded the human papillomavirus (HPV) vaccine and identified the virus as a primary cause ...

Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.

Angelina Jolie shows mastectomy scars to spotlight breast health on TIME France. The Oscar-winning actor appears on the first ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...